Swedish Life Sciences Stock News

OM:EQT
OM:EQTCapital Markets

Is There Now An Opportunity In EQT (OM:EQT) After The Recent 30 Day Pullback

If you are looking at EQT and wondering whether the current share price still offers value, this article will walk you through what the numbers actually say about the stock. The share price last closed at SEK 290.30, with returns of 2.0% over 7 days, a 19.4% decline over 30 days, and returns of 20.7% over 3 years and 21.8% over 5 years that give useful longer term context. Recent coverage of EQT has focused on how the stock's shorter term pullback sits against its longer term record. This...
OM:CAMX
OM:CAMXPharmaceuticals

Why Camurus (OM:CAMX) Is Down 24.8% After Lifting 2026 Guidance and Showcasing Oxyesa Progress

Camurus AB reported its fourth-quarter and full-year 2025 results, with full-year sales rising to SEK 2,265.38 million and net income to SEK 735.57 million, while issuing 2026 guidance for revenues of SEK 2.60–2.90 billion and operating result of SEK 0.90–1.20 billion. Alongside these results, Camurus highlighted 2025 milestones including EU and UK approvals for Oxyesa in acromegaly and progress in long-acting metabolic therapies, underlining how its product pipeline and regulatory traction...
OM:LATO B
OM:LATO BIndustrials

Latour (OM:LATO B) Margin Compression Challenges Long Term Quality Investor Narrative

Investment AB Latour (OM:LATO B) has wrapped up FY 2025 with Q4 revenue of SEK7.4b and basic EPS of SEK2.50, while the trailing twelve months show revenue of SEK28.1b and EPS of SEK7.69 against a backdrop of weaker earnings compared with the prior year and a lower net margin of 17.5% versus 23.8%. Over recent quarters, revenue has moved from SEK7.0b in Q4 2024 to SEK7.4b in Q4 2025, with quarterly EPS shifting from SEK2.29 to SEK2.50 as the twelve month EPS line eased from SEK9.65 to SEK7.69...
OM:EMBRAC B
OM:EMBRAC BEntertainment

Embracer Group (OM:EMBRAC B) Valuation Check After Volatile Share Price Performance

What recent performance says about Embracer Group (OM:EMBRAC B) Embracer Group (OM:EMBRAC B) has seen its share price move sharply in different directions, with a 19% gain over the past week and a 38% decline over the past 3 months. This places recent momentum in contrast with a weaker medium term trend. See our latest analysis for Embracer Group. At a share price of SEK54.47, Embracer Group’s sharp 18.7% 7 day share price return comes after a weaker stretch, with the 1 year total shareholder...
OM:VIMIAN
OM:VIMIANMedical Equipment

Global Stocks Trading Below Estimated Value In February 2026

As global markets navigate a period of mixed performance, with technology stocks facing challenges and value-oriented segments gaining traction, investors are keenly observing the shifts in economic indicators such as cooling U.S. labor data and fluctuating manufacturing activity. In this context, identifying undervalued stocks can be particularly appealing as they may offer potential opportunities for growth amidst the broader market volatility and sector rotations.
OM:SEB A
OM:SEB ABanks

Is It Time To Reconsider SEB (OM:SEB A) After Recent Share Price Pullback?

If you are wondering whether Skandinaviska Enskilda Banken shares still offer value after a long run in the market, you are in the right place for a closer look at what the current price might be baking in. The stock last closed at SEK191.0, with returns of a 1.3% decline over 7 days, a 4.8% decline over 30 days and a 3.5% decline year to date, while the 1 year return stands at 24.6%, the 3 year return at 83.8% and the 5 year return at 176.3%. Recent news coverage around Skandinaviska...
OM:ERIC B
OM:ERIC BCommunications

Is Ericsson (OM:ERIC B) Fairly Priced After Mixed Recent Share Price Performance?

If you are wondering whether Telefonaktiebolaget LM Ericsson’s current share price fairly reflects its potential, you are not alone. Many investors are asking the same question before making their next move. The stock last closed at SEK 97.2, with returns of a 2.3% decline over 7 days, 11.7% over 30 days, 10.1% year to date, 18.1% over 1 year, 81.0% over 3 years and 5.8% over 5 years. This gives investors plenty to think about in terms of changing sentiment and risk. Recent news coverage...
OM:VIMIAN
OM:VIMIANMedical Equipment

Vimian Group (OM:VIMIAN) Valuation Check After Strong 2025 Results And New Acquisitions

Vimian Group (OM:VIMIAN) is back in focus after its fourth quarter and full year 2025 earnings, where double digit revenue and adjusted EBITDA growth, along with a higher full year net income, drew fresh investor attention. See our latest analysis for Vimian Group. The earnings release and earlier 2025 earnings call seem to have reset sentiment, with the latest move to SEK27.94 coming after a 1 day share price return of 11.14%, against a weaker 1 year total shareholder return of 37% and a...
OM:SINCH
OM:SINCHSoftware

Sinch (OM:SINCH) Valuation Check As Lovable Partnership Highlights Role In AI Communications

What the Lovable partnership could mean for Sinch Sinch (OM:SINCH) has just announced a partnership with Lovable, integrating its communications tools into the Lovable Cloud to support AI-built applications and production workloads across email, messaging, and voice. The collaboration starts with Sinch's Mailgun platform for email and could broaden into wider omnichannel services as Lovable users move from early prototypes to live customer facing products. See our latest analysis for...
OM:IVSO
OM:IVSOAerospace & Defense

3 European Stocks Estimated To Be Up To 49.8% Below Intrinsic Value

As the European markets continue to show resilience amid global volatility, optimism about the eurozone economy has supported investor sentiment, with major indices like Germany's DAX and France's CAC 40 posting gains. In this environment of cautious optimism and stable interest rates from the European Central Bank, identifying undervalued stocks becomes crucial for investors looking to capitalize on potential market opportunities.
OM:HNSA
OM:HNSABiotechs

Hansa Biopharma (OM:HNSA) Heavy SEK 529 Million TTM Losses Test Bullish Turnaround Narrative

Hansa Biopharma (OM:HNSA) has reported full year 2025 results with fourth quarter revenue of SEK 76.0 million and a basic EPS loss of SEK 1.62, alongside a trailing twelve month EPS loss of SEK 6.52 on revenue of SEK 222.3 million. The company has seen quarterly revenue move between SEK 30.8 million and SEK 76.0 million across 2025, while quarterly basic EPS stayed in loss-making territory, ranging from SEK 0.55 to SEK 2.53 per share. For investors, the latest print keeps the focus squarely...
OM:CAMX
OM:CAMXPharmaceuticals

Assessing Camurus (OM:CAMX) Valuation After New 2026 Growth Guidance And Portfolio Progress

Why Camurus’ new 2026 guidance matters for shareholders Camurus (OM:CAMX) has set fresh 2026 guidance, flagging expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, alongside several portfolio milestones. See our latest analysis for Camurus. Camurus’ new 2026 guidance follows a 9.5% year to date share price return and a 14.2% total shareholder return over the past year, which builds on a very large 3 year total shareholder return of about 19x. This...
OM:SKA B
OM:SKA BConstruction

Skanska (OM:SKA B) Valuation Check After New US And UK Infrastructure Contract Wins

Skanska (OM:SKA B) has been busy adding new work, with fresh contracts in US transport and education, and UK offices that feed directly into its order book and future earnings pipeline. See our latest analysis for Skanska. At a latest share price of SEK266.6, Skanska has seen a 1-day share price return of 0.91% and a 7-day share price return decline of 3.93%, while a 90-day share price return of 7.72% and a 1-year total shareholder return of 8.10% suggest momentum that lines up with a steady...
OM:PDX
OM:PDXEntertainment

Assessing Paradox Interactive (OM:PDX) Valuation After Weaker Earnings And A Higher Proposed Dividend

Paradox Interactive (OM:PDX) just reported full year 2025 results that paired weaker profitability with a higher proposed dividend, a combination that is drawing fresh attention to the stock’s recent performance. See our latest analysis for Paradox Interactive. The annual results appear to have reset expectations, with the 1 month share price return of 19.47% and 3 month share price return of 27.00% weighing on sentiment. At the same time, the 1 year total shareholder return of 41.43% shows...
OM:ZZ B
OM:ZZ BRetail Distributors

3 European Dividend Stocks Offering Up To 5.5% Yield

As the European market continues to show resilience amidst global volatility, with the pan-European STOXX Europe 600 Index reaching new highs and major indexes like Germany's DAX and France's CAC 40 posting gains, investors are increasingly optimistic about the eurozone economy. In this environment of cautious optimism, dividend stocks can offer a compelling opportunity for income-focused investors seeking stability and potential returns; these stocks typically provide regular payouts that...